About the Project
In this project, we aim to validate the in vivo b-catenin iDamID using pericentral hepatocytes, in which Wnt/b-catenin is known to control metabolic gene expression. Subsequently we will perform the same in vivo b-catenin iDamID in a non-alcoholic fatty liver disease (NAFLD) model with high fat diet (HFD). NAFLD is the most common cause of liver disease, strongly associated with the metabolic syndrome, including obesity, insulin resistance, type 2 diabetes and dyslipidemia, a growing problem in modern society with a $20 billion to $35 billion per year drug market value by 2025. Hepatocytes with high Wnt/b-catenin signalling preferentially accumulates lipid droplets under HFD, and hepatocyte-specific b-catenin knockout (KO) and overexpression (OE) results in milder and severer hepatic steatosis under HFD, respectively. However, gene expression of b-catenin KO or OE hepatocytes under normal diet indicates that Wnt/b-catenin signalling rather suppresses lipogenesis, and it is not clear why active Wnt/b-catenin signalling correlates with severer lipid droplets accumulation in NAFLD. Thus, we hypothesize that direct Wnt/b-catenin targets in hepatocytes changes depending on diet, and address this hypothesis with in vivo iDamID.
In parallel, we will also develop lentiviral b-catenin iDamID system which is applicable to human primary cell culture, and complement the mouse in vivo DamID system. Once the system is established and validated with mouse ES cells, we will apply it to 3D primary human hepatocyte spheroid culture, in the presence and absence of hepatic steatosis inducers, free fatty acids and insulin, known to activate Wnt/b-catenin signalling. These human hepatocytes b-catenin DamID-seq data will be compared to the mouse in vivo data, and used to identify liver disease associated SNPs overlap with the b-catenin binding sites.
In summary, this project will provide the research community with powerful and widely applicable tools to identify direct Wnt/b-catenin targets with minimal cell numbers, demonstrating their application in fundamental liver biology.
This 4 year PhD project is part of a competition funded by EASTBIO BBSRC Doctoral Training Partnership (DTP) http://www.eastscotbiodtp.ac.uk/how-apply-0.
EASTBIO Application, Equality, Diversity and Inclusion (EDI) survey and Reference Forms can be downloaded via http://www.eastscotbiodtp.ac.uk/how-apply-0
Please send your completed EASTBIO Application Form and EDI survey along with a copy of your academic transcripts to email@example.com before the deadline.
You should also ensure that two references have been sent to firstname.lastname@example.org by the deadline using the EASTBIO Reference Form.
Please refer to UKRI website and Annex B of the UKRI Training Grant Terms and Conditions for full eligibility criteria.
Why not add a message here
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.
Using ex-vivo genetic systems as models to detect genetic susceptibility to co-morbidities in Covid 19 infection, and to test specific anti-inflammatory / antiviral drugs in Covid 19 infection
University of Bradford